Medigen Vaccine Biologics (TWO:6547) — Stock Price
Medigen Vaccine Biologics (TWO:6547) is currently trading at NT$51.90 TWD, up 0.58% today. Over the past 52 weeks, shares have ranged between NT$33.75 and NT$61.00. This page tracks Medigen Vaccine Biologics's live share price on the TWO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see how much is Medigen Vaccine Biologics worth.
Medigen Vaccine Biologics (6547) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Medigen Vaccine Biologics's daily closing share price and trading volume on the TWO exchange over the past year, giving a clear view of recent price momentum and liquidity.
Medigen Vaccine Biologics Income Statement — Revenue, Profit & Earnings by Year
Medigen Vaccine Biologics's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | NT$613.17 Million | NT$605.64 Million | NT$389.62 Million | NT$365.04 Million | NT$3.28 Billion |
| Cost of Revenue | NT$248.50 Million | NT$209.22 Million | NT$168.48 Million | NT$577.64 Million | NT$975.96 Million |
| Gross Profit | NT$364.67 Million | NT$396.42 Million | NT$221.15 Million | NT$-212.60 Million | NT$2.31 Billion |
| Research & Development | NT$338.57 Million | NT$221.51 Million | NT$1.19 Billion | NT$1.14 Billion | NT$1.19 Billion |
| SG&A | NT$291.79 Million | NT$320.57 Million | NT$86.49 Million | NT$110.84 Million | NT$140.71 Million |
| Total Operating Expenses | NT$878.86 Million | NT$751.30 Million | NT$1.43 Billion | NT$1.32 Billion | NT$1.34 Billion |
| Operating Income | NT$-265.69 Million | NT$-145.67 Million | NT$-1.21 Billion | NT$-1.45 Billion | NT$1.42 Billion |
| EBITDA | — | — | NT$-1.08 Billion | NT$-1.32 Billion | NT$1.53 Billion |
| EBIT | — | — | NT$-1.21 Billion | NT$-1.45 Billion | NT$1.42 Billion |
| Interest Expense | NT$8.80 Million | NT$18.89 Million | NT$37.57 Million | NT$26.89 Million | NT$6.02 Million |
| Income Before Tax | NT$-281.71 Million | NT$-80.47 Million | NT$-1.16 Billion | NT$-1.47 Billion | NT$1.41 Billion |
| Income Tax Expense | — | — | NT$1.00 | NT$26.89 Million | NT$6.02 Million |
| Net Income | NT$-281.71 Million | NT$-80.47 Million | NT$-1.16 Billion | NT$-1.50 Billion | NT$1.41 Billion |
Medigen Vaccine Biologics Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Medigen Vaccine Biologics's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | NT$3.93 Billion | NT$4.36 Billion | NT$6.09 Billion | NT$7.35 Billion | NT$5.30 Billion |
| Total Current Assets | NT$2.36 Billion | NT$2.56 Billion | NT$4.40 Billion | NT$5.46 Billion | NT$3.72 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | NT$1.18 Billion | NT$1.20 Billion | NT$2.40 Billion | NT$3.03 Billion | NT$853.10 Million |
| Net Receivables | NT$130.02 Million | NT$118.03 Million | NT$198.84 Million | NT$566.56 Million | NT$719.89 Million |
| Inventory | NT$393.75 Million | NT$452.06 Million | NT$383.63 Million | NT$544.78 Million | NT$563.50 Million |
| Property, Plant & Equipment | — | — | — | NT$1.47 Billion | NT$1.41 Billion |
| Goodwill | — | — | — | — | — |
| Total Liabilities | NT$454.64 Million | NT$513.92 Million | NT$2.25 Billion | NT$2.32 Billion | NT$622.95 Million |
| Total Current Liabilities | NT$185.04 Million | NT$214.22 Million | NT$1.99 Billion | NT$355.23 Million | NT$439.09 Million |
| Long-term Debt | — | — | NT$0.00 | NT$1.68 Billion | NT$0.00 |
| Net Debt | — | — | NT$621.54 Million | NT$752.31 Million | NT$-1.19 Billion |
| Total Stockholder Equity | NT$3.48 Billion | NT$3.85 Billion | NT$3.85 Billion | NT$5.03 Billion | NT$4.68 Billion |
| Retained Earnings | NT$-281.71 Million | NT$-80.47 Million | NT$-1.16 Billion | NT$-1.27 Billion | NT$1.41 Billion |
Medigen Vaccine Biologics Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Medigen Vaccine Biologics generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | NT$-49.09 Million | NT$40.75 Million | NT$-477.75 Million | NT$-1.10 Billion | NT$579.89 Million |
| Capital Expenditures | NT$51.78 Million | NT$34.98 Million | NT$40.95 Million | NT$140.34 Million | NT$134.97 Million |
| Free Cash Flow | NT$-100.86 Million | NT$5.77 Million | NT$-518.71 Million | NT$-1.24 Billion | NT$444.92 Million |
| Investing Cash Flow | — | — | — | NT$-2.40 Billion | NT$-930.69 Million |
| Financing Cash Flow | — | — | NT$1.01 Million | NT$3.32 Billion | NT$51.18 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | NT$31.00 Million | NT$14.16 Million | NT$18.30 Million | NT$75.61 Million | NT$68.81 Million |
| Depreciation | NT$141.79 Million | NT$136.44 Million | NT$131.17 Million | NT$127.89 Million | NT$112.54 Million |
| Change in Cash | NT$-123.58 Million | NT$-677.51 Million | NT$173.70 Million | NT$-175.44 Million | NT$-299.73 Million |
Medigen Vaccine Biologics Earnings History — EPS Actual vs. Analyst Estimates
Track Medigen Vaccine Biologics's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.09 | 0.03 | -400.00% |
| Mar 13, 2026 | -0.42 | 0.09 | -566.67% |
| Nov 13, 2025 | -0.07 | 0.07 | -200.00% |
| Aug 13, 2025 | -0.30 | 0.08 | -475.00% |
| May 15, 2025 | -0.06 | — | — |
| Mar 05, 2025 | -0.06 | -0.01 | -500.00% |
| Nov 04, 2024 | — | — | — |
| Mar 08, 2024 | -1.77 | -0.49 | -261.22% |